LinkedIn Profile

Access Sunesis Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:snss 166198 Apr 21st, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 21st, 2024 03:17AM Apr 21st, 2024 03:17AM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 20th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 20th, 2024 12:05AM Apr 20th, 2024 05:39PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 19th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 19th, 2024 04:40AM Apr 19th, 2024 04:40AM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 18th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 18th, 2024 12:49AM Apr 18th, 2024 07:00PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 17th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 17th, 2024 12:03AM Apr 17th, 2024 03:26PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 16th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 15th, 2024 11:59PM Apr 16th, 2024 11:42AM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 15th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 14th, 2024 11:54PM Apr 15th, 2024 05:23PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 14th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 13th, 2024 11:43PM Apr 13th, 2024 11:43PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 13th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 12th, 2024 11:35PM Apr 13th, 2024 12:08PM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology
nasdaq:snss 166198 Apr 12th, 2024 12:00AM Sunesis Pharmaceuticals, Inc. 2.4K 43.00 Open Apr 11th, 2024 11:41PM Apr 12th, 2024 09:04AM Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia. The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business. • Our work—pursuing the best possible translational and clinical science to ensure that we deliver important new drugs to patients • Our workplace—creating a stimulating, teamwork-oriented environment for our people involved in this important work • Our world—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers Open Open 395 Oyster Point Blvd. South San Francisco CA US 94080 Sunesis Pharmaceuticals Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.